353 related articles for article (PubMed ID: 37928547)
21. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
22. Recent Developments in Glioblastoma Therapy: Oncolytic Viruses and Emerging Future Strategies.
Hamad A; Yusubalieva GM; Baklaushev VP; Chumakov PM; Lipatova AV
Viruses; 2023 Feb; 15(2):. PubMed ID: 36851761
[TBL] [Abstract][Full Text] [Related]
23. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
[TBL] [Abstract][Full Text] [Related]
24. Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancer.
Crupi MJF; Taha Z; Janssen TJA; Petryk J; Boulton S; Alluqmani N; Jirovec A; Kassas O; Khan ST; Vallati S; Lee E; Huang BZ; Huh M; Pikor L; He X; Marius R; Austin B; Duong J; Pelin A; Neault S; Azad T; Breitbach CJ; Stojdl DF; Burgess MF; McComb S; Auer R; Diallo JS; Ilkow CS; Bell JC
Front Immunol; 2022; 13():1029269. PubMed ID: 36405739
[TBL] [Abstract][Full Text] [Related]
25. Advances and challenges: dendritic cell vaccination strategies for glioblastoma.
Schaller TH; Sampson JH
Expert Rev Vaccines; 2017 Jan; 16(1):27-36. PubMed ID: 27500911
[TBL] [Abstract][Full Text] [Related]
26. Oncolytic Viruses: Priming Time for Cancer Immunotherapy.
Russell L; Peng KW; Russell SJ; Diaz RM
BioDrugs; 2019 Oct; 33(5):485-501. PubMed ID: 31321623
[TBL] [Abstract][Full Text] [Related]
27. Immunotherapy Resistance in Glioblastoma.
Wang EJ; Chen JS; Jain S; Morshed RA; Haddad AF; Gill S; Beniwal AS; Aghi MK
Front Genet; 2021; 12():750675. PubMed ID: 34976006
[TBL] [Abstract][Full Text] [Related]
28. MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation.
Bommareddy PK; Aspromonte S; Zloza A; Rabkin SD; Kaufman HL
Sci Transl Med; 2018 Dec; 10(471):. PubMed ID: 30541787
[TBL] [Abstract][Full Text] [Related]
29. Agent-Based Modelling Reveals the Role of the Tumor Microenvironment on the Short-Term Success of Combination Temozolomide/Immune Checkpoint Blockade to Treat Glioblastoma.
Surendran A; Jenner AL; Karimi E; Fiset B; Quail DF; Walsh LA; Craig M
J Pharmacol Exp Ther; 2023 Oct; 387(1):66-77. PubMed ID: 37442619
[TBL] [Abstract][Full Text] [Related]
30. Oncolytic adenovirus ORCA-010 increases the type 1 T cell stimulatory capacity of melanoma-conditioned dendritic cells.
López González M; van de Ven R; de Haan H; van Eck van der Sluijs J; Dong W; van Beusechem VW; de Gruijl TD
Clin Exp Immunol; 2020 Aug; 201(2):145-160. PubMed ID: 32301504
[TBL] [Abstract][Full Text] [Related]
31. Current Advances in Immunotherapy for Glioblastoma.
Mende AL; Schulte JD; Okada H; Clarke JL
Curr Oncol Rep; 2021 Jan; 23(2):21. PubMed ID: 33496872
[TBL] [Abstract][Full Text] [Related]
32. Immunovirotherapy: The role of antibody based therapeutics combination with oncolytic viruses.
Jafari M; Kadkhodazadeh M; Shapourabadi MB; Goradel NH; Shokrgozar MA; Arashkia A; Abdoli S; Sharifzadeh Z
Front Immunol; 2022; 13():1012806. PubMed ID: 36311790
[TBL] [Abstract][Full Text] [Related]
33. Dendritic cell vaccine of gliomas: challenges from bench to bed.
Zheng Y; Ma X; Feng S; Zhu H; Chen X; Yu X; Shu K; Zhang S
Front Immunol; 2023; 14():1259562. PubMed ID: 37781367
[TBL] [Abstract][Full Text] [Related]
34. Immunotherapeutic Potential of Oncolytic H-1 Parvovirus: Hints of Glioblastoma Microenvironment Conversion towards Immunogenicity.
Angelova AL; Barf M; Geletneky K; Unterberg A; Rommelaere J
Viruses; 2017 Dec; 9(12):. PubMed ID: 29244745
[TBL] [Abstract][Full Text] [Related]
35. Immune Escape in Glioblastoma: Mechanisms of Action and Implications for Immune Checkpoint Inhibitors and CAR T-Cell Therapy.
Yu C; Hsieh K; Cherry DR; Nehlsen AD; Resende Salgado L; Lazarev S; Sindhu KK
Biology (Basel); 2023 Dec; 12(12):. PubMed ID: 38132354
[TBL] [Abstract][Full Text] [Related]
36. Dendritic cell vaccine trials in gliomas: Untangling the lines.
Hotchkiss KM; Batich KA; Mohan A; Rahman R; Piantadosi S; Khasraw M
Neuro Oncol; 2023 Oct; 25(10):1752-1762. PubMed ID: 37289203
[TBL] [Abstract][Full Text] [Related]
37. Hallmarks of the Tumour Microenvironment of Gliomas and Its Interaction with Emerging Immunotherapy Modalities.
Linares CA; Varghese A; Ghose A; Shinde SD; Adeleke S; Sanchez E; Sheriff M; Chargari C; Rassy E; Boussios S
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686020
[TBL] [Abstract][Full Text] [Related]
38. Challenges in the Treatment of Glioblastoma by Chimeric Antigen Receptor T-Cell Immunotherapy and Possible Solutions.
Zhang P; Zhang Y; Ji N
Front Immunol; 2022; 13():927132. PubMed ID: 35874698
[TBL] [Abstract][Full Text] [Related]
39. GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma.
Gargett T; Ebert LM; Truong NTH; Kollis PM; Sedivakova K; Yu W; Yeo ECF; Wittwer NL; Gliddon BL; Tea MN; Ormsby R; Poonnoose S; Nowicki J; Vittorio O; Ziegler DS; Pitson SM; Brown MP
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36167468
[TBL] [Abstract][Full Text] [Related]
40. The current state of immunotherapy for gliomas: an eye toward the future.
Fecci PE; Sampson JH
J Neurosurg; 2019 Sep; 131(3):657-666. PubMed ID: 31473668
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
